Clinical Trial Update: CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial compares the CTOP/ITE/MTX regimen against CHOP as first-line therapy for newly diagnosed young patients with various T-cell lymphomas; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma Alk-negative
• Angioimmunoblastic T-cell Lymphoma
• Enteropathy-associated T-cell Lymphoma
• Hepatosplenic T-cell Lymphoma
• Peripheral T-cell Lymphoma Not Otherwise Specified
• Subcutaneous Panniculitis-like T-cell Lymphoma

Drugs mentioned

• CHOP regimen
• CTOP/ITE/MTX regimen

Snippet

Sponsor: Ruijin Hospital | Conditions: ALK-negative Anaplastic Large Cell Lymphoma, Peripherial T Cell Lymphoma,Not Otherwise Specified | Phase 4 | Status: UNKNOWN